Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

被引：4
|
作者：
Rodrigues, M. J. [1 ,2 ]
Albiges-Sauvin, L. [2 ,3 ]
Wassermann, J. [2 ,4 ]
Cottu, P. H. [1 ]
机构：
[1] Inst Curie, Dept Med Oncol, Paris, France
[2] AERIO, Paris, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Hop Rene Huguenin, Inst Curie, Dept Med Oncol, St Cloud, France
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 11期
关键词：
CANCER;
D O I：
10.1093/annonc/mdr308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2530 / 2530
页数：1
相关论文
共 50 条
  • [21] FOR WHICH PT1A, BN0M0 HORMONE RESPONSIVE INVASIVE BREAST CARCINOMAS COULD ENDOCRINE THERAPY BE AVOIDED?
    Perrin, C.
    Edeline, J.
    Leseur, J.
    Lavoue, V.
    Tas, P.
    Mesbah, H.
    Lefeuvre-Plesse, C.
    Gedouin, D.
    Penault-Llorca, F.
    Kerbrat, P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 105 - 105
  • [22] Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
    Iwata, Hiroji
    Masuda, Norikazu
    Kim, Sung-Bae
    Inoue, Kenichi
    Rai, Yoshiaki
    Fujita, Takashi
    Chiu, Joanne
    Ohtani, Shoichiro
    Takahashi, Masato
    Miyaki, Toshiko
    Lu, Yen-Shen
    Xu, Binghe
    Yap, Yoon Sim
    Bustam, Anita
    Yao, Bin
    Zhang, Bo
    Bryce, Richard
    Chan, Arlene
    [J]. FUTURE ONCOLOGY, 2019, 15 (21) : 2489 - 2501
  • [23] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [24] Utilization of adjuvant trastuzumab for T1a,b N0 HER2+breast cancer in Ontario.
    Eisen, Andrea
    Yeung, Lyndee
    Gavura, Scott
    Brown, Zachary M.
    Trudeau, Maureen E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Disease-related outcomes with adjuvant chemotherapy in HER2 positive or triple negative T1a/bN0 breast cancers
    Shao, T.
    Olszewski, A. J.
    Boolbol, S. K.
    Migdady, Y.
    Boachie-Adjei, K.
    Sakr, B. J.
    Klein, P.
    Sikov, W.
    [J]. CANCER RESEARCH, 2012, 72
  • [26] Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
    Montemurro, Filippo
    Donadio, Michela
    Clavarezza, Matteo
    Redana, Stefania
    Jacomuzzi, Maria Elena
    Valabrega, Giorgio
    Danese, Saverio
    Vietti-Ramus, Guido
    Durando, Antonio
    Venturini, Marco
    Aglietta, Massimo
    [J]. ONCOLOGIST, 2006, 11 (04): : 318 - 324
  • [27] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Anthony F. Yu
    Roy B. Mukku
    Shivani Verma
    Jennifer E. Liu
    Kevin C. Oeffinger
    Richard M. Steingart
    Clifford A. Hudis
    Chau T. Dang
    [J]. Breast Cancer Research and Treatment, 2017, 166 : 241 - 247
  • [28] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Yu, Anthony F.
    Mukku, Roy B.
    Verma, Shivani
    Liu, Jennifer E.
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 241 - 247
  • [29] EFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER
    Sendur, M. A.
    Aksoy, S.
    Uncu, D.
    Demir, H.
    Yuksel, S.
    Ekinci, A. S.
    Kaplan, A.
    Ustaalioglu, B. B.
    Tufan, G.
    Inanc, M.
    Ozdemir, N.
    Artac, M.
    Tastekin, D.
    Kacan, T.
    Oguz, A.
    Arpaci, E.
    Yazilitas, D.
    Gumus, M.
    Zengin, N.
    Altundag, M. K.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [30] A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer
    Yap, Kelly Khai Li
    Tripathy, Debu
    [J]. AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (01) : 11 - 15
12345